0000950103-21-012388.txt : 20210816 0000950103-21-012388.hdr.sgml : 20210816 20210816172658 ACCESSION NUMBER: 0000950103-21-012388 CONFORMED SUBMISSION TYPE: NT 10-Q PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20210630 FILED AS OF DATE: 20210816 DATE AS OF CHANGE: 20210816 EFFECTIVENESS DATE: 20210816 FILER: COMPANY DATA: COMPANY CONFORMED NAME: European Biotech Acquisition Corp. CENTRAL INDEX KEY: 0001841258 STANDARD INDUSTRIAL CLASSIFICATION: BLANK CHECKS [6770] IRS NUMBER: 000000000 STATE OF INCORPORATION: E9 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: NT 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-40211 FILM NUMBER: 211179974 BUSINESS ADDRESS: STREET 1: JOHANNES VERMEERPLEIN 9 1071 DV CITY: AMSTERDAM STATE: P7 ZIP: 00000 BUSINESS PHONE: 31 (0) 20 664 55 00 MAIL ADDRESS: STREET 1: JOHANNES VERMEERPLEIN 9 1071 DV CITY: AMSTERDAM STATE: P7 ZIP: 00000 NT 10-Q 1 dp156316_nt10q.htm FORM NT 10-Q

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 12b-25

 

NOTIFICATION OF LATE FILING

 

 

(Check one):  

¨ Form 10-K ¨ Form 20-F ¨ Form 11-K x Form 10-Q

¨ Form 10-D ¨ Form N-SAR ¨ Form N-CSR

   
    For Period Ended: June 30, 2021
   
    ¨ Transition Report on Form 10-K
    ¨ Transition Report on Form 20-F
    ¨ Transition Report on Form 11-K
    ¨ Transition Report on Form 10-Q
    ¨ Transition Report on Form N-SAR
    ¨ For the Transition Period Ended:

 

 

If the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates:

 

 

 

PART I - REGISTRANT INFORMATION

 

European Biotech Acquisition Corp.

Full Name of Registrant

 

N/A

Former Name if Applicable

 

Johannes Vermeerplein 9

Address of Principal Executive Office (Street and Number)

 

1071 DV Amsterdam, Netherlands

City, State and Zip Code

 

 
 

 

PART II - RULES 12b-25(b) AND (c)

 

If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed. (Check box if appropriate)

 

x

   (a)   The reason described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense
  (b)   The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, Form 11-K, Form N-SAR or Form N-CSR, or portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report or transition report on Form 10-Q or subject distribution report on Form 10-D, or portion thereof, will be filed on or before the fifth calendar day following the prescribed due date; and
  (c)   The accountant’s statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.

  

 

  

PART III - NARRATIVE

 

State below in reasonable detail why Forms 10-K, 20-F, 11-K, 10-Q, 10-D, N-SAR, N-CSR, or the transition report or portion thereof, could not be filed within the prescribed time period.

 

European Biotech Acquisition Corp. (the “Registrant”) is unable to file its Quarterly Report on Form 10-Q for the fiscal quarter ended June 30, 2021 by the prescribed due date because the review of the Registrant’s financial statements to be included in the Form 10-Q has not yet been completed. The Registrant is filing a Form 12b-25 for a 5 day extension, and currently anticipates that it will file the Form 10-Q as soon as practicable on or before the fifth calendar day following the prescribed due date.

 

 

PART IV - OTHER INFORMATION

 

(1)Name and telephone number of person to contact in regard to this notification

 

Koen Sintnicolaas   31 (0)   20 664 55 00
(Name)   (Area Code)   (Telephone Number)

 

(2)Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed? If answer is no, identify report(s). Yes x No ¨

 

(3)Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof? Yes x No ¨

 

 
 

If so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.

 

We are required by Part IV, Item (3) of Form 12b-25 to provide as part of this filing an explanation regarding whether the results of operations we expect to report for the quarter ended June 30, 2021 will reflect significant changes from our results of operations for the quarter ended June 30, 2020. Because our company did not exist during the quarter ended June 30, 2020, we are unable to provide a response to this requirement.

 

  

European Biotech Acquisition Corp. 

(Name of Registrant as Specified in Charter)

 

has caused this notification to be signed on its behalf by the undersigned hereunto duly authorized.

             
Date:   August 16, 2021   By:   /s/ Koen Sintnicolaas
        Name:   Koen Sintnicolaas
        Title:   Chief Financial Officer